Establishing a successful outpatient CAR T-Cell program with cilta-cel: real-world experience from an expert roundtable
Open Access
- 18 March 2025
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 21 (10) , 1137-1144
Abstract
In less than a decade since their first approval, chimeric antigen receptor T-cell (CAR-T) therapies have moved into earlier lines of therapy, shifting administration from an inpatient to an outpatient setting and increasing patient demand. Several CAR-T outpatient programs have been initiated to meet patient and institution needs, resulting in resource conservation, increased treatment capacity, reduced hospitalization times, and financial advantages. Ciltacabtagene autoleucel (cilta-cel) is uniquely suited for outpatient administration, given its predictably delayed cytokine release syndrome and immune-effector cell-associated neurotoxicity syndrome profile in adult patients with relapsed or refractory multiple myeloma (MM). Given the evolution of MM treatment, the distinct safety profile of cilta-cel, limited hospital capacities, cost considerations, and patient preference, outpatient administration of cilta-cel is becoming a critical part of ensuring increased access to CAR-T therapy in a timely manner to most, if not all, eligible patients. To highlight the practical aspects of cilta-cel outpatient programs and to facilitate the establishment of similar initiatives at other clinics, a group of hematology/oncology specialists with expertise in myeloma and cellular therapies participated in a roundtable discussion. They shared their real-world experiences, provided insights on feasibility, safety, and effectiveness, and identified key success factors to prepare institutions, patients, and caregivers.Keywords
Funding Information
- Janssen Pharmaceuticals, Inc
- Legend Biotech USA Inc
This publication has 31 references indexed in Scilit:
- Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS DataTransplantation and Cellular Therapy, 2024
- Real‐world practitioner perceptions of CARTITUDE‐4 results for patients with previously treated multiple myelomaeJHaem, 2024
- Carvykti (cilta-cel) Real World Outcomes across the Sarah Cannon Transplant Cell Therapy NetworkTransplantation and Cellular Therapy, 2024
- Evaluation of Outpatient Administration of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: Single Center ExperienceTransplantation and Cellular Therapy, 2024
- Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyTransplantation and Cellular Therapy, 2023
- Patient Perceptions of CAR-T Therapy in the USA: Findings from In-Depth InterviewsOncology and Therapy, 2023
- Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin LymphomaTransplantation and Cellular Therapy, 2023
- Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like SyndromeTransplantation and Cellular Therapy, 2023
- Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution ExperienceTransplantation and Cellular Therapy, 2023
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019